Intuitive Ventures’ Post

Progentos Therapeutics Secures $65 Million Series A To Advance MS Treatment Learn more & get our take 👇 https://lnkd.in/gQjEwDh9 “While there are many treatments that are highly effective at slowing the progression of disease, there is a significant unmet need for new approaches that can regenerate myelin and restore function for patients with MS,” – Dr. Chris Loose, PhD, CEO at Progentos “We are truly excited to be part of Progentos’ journey towards delivering potentially disease-modifying drugs for diseases like multiple sclerosis, diseases with high unmet clinical needs,” – Dr. Dmitrij Hristodorov, Ph.D., General Partner at Forbion #funding #mstreatment #SoHCNews

World Glaucoma Week aims to raise awareness and promote understanding of the crucial need for early detection of glaucoma, which ranks as the world’s second leading cause of blindness. EV is honored to count The Glaucoma Foundation as an investor. Founded in 1984, The mission of TGF is to develop a cure for glaucoma through research and collaboration. This week the Glaucoma Foundation has been sharing a “Living With Glaucoma” series, which you can read on their LinkedIn and website. TGF will also be hosting a black-tie gala in New York City on April 18th, with honorees including David Letterman and Barry Friedberg. ExSight Ventures would like to recognize 3 of the companies that are developing treatments for Glaucoma: Elios Vision is developing technology for treating glaucoma, which involves a laser system that creates implant-free microchannels along the trabecular meshwork to improve aqueous flow and reduce intraocular pressure (IOP). The technology is undergoing FDA pivotal trials for both combination and standalone procedures, with an estimated launch in early 2025. ONL Therapeutics aims to provide IOP-independent neuroprotection for glaucoma. They plan to report topline results for retinal detachment in April-May, progress to a registrational study for GA in 2024, and explore neuroenhancement in glaucoma with a potential Phase 2 study in 2025. Novai continues to demonstrate how its AI-assisted DARC technology can help accelerate and de-risk clinical drug development in Glaucoma, wet AMD, and Geographic Atrophy. #worldglaucomaweek #eyehealth #eyehealthmatters #glaucomaawareness #glaucoma

Corcept Therapeutics Reports Completion of Patient Recruitment in the P-II Study of Dazucorilant for the Treatment of Amyotrophic Lateral Sclerosis (ALS) #corcepttherapeutics #dazucorilant #amyotrophiclateralsclerosis #clinicaltrial #phase2 #als #safety #treatment #patientrecruitment #dazals #us #canada #glucocorticoidreceptor #neurologicdisorders

Lisa Ricciardi of Cognition Therapeutics, Inc., one of our Cowtown Angels portfolio companies, was recently featured in BioSpace talking about their trial candidate, CT1812, that prevents the binding of toxic oligomers to synapses in a neuroprotective approach that acts earlier in the amyloid cascade to slow cognitive decline and disease progression. Their Phase II trial is underway with 540 early-to-mild Alzheimer’s patients. Results from an earlier Phase II trial are expected mid-summer. Are you an accredited investor looking for quality investment opportunities from top emerging companies? Learn more about Cowtown Angels here: https://lnkd.in/eF8x7_VX

We're thrilled to announce that Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) has received FDA Orphan Drug Designation for CELZ-101, a groundbreaking therapy set to revolutionize transplantation therapy in the treatment of brittle Type 1 diabetes.    CELZ-101, also known as Supercharged Treg Biologic Immunotherapy (ImmCelzTM), represents a cutting-edge approach in personalized medicine, utilizing the patient's own regulatory T cells (Tregs) to combat autoimmune responses and prevent allograft rejection in pancreatic islet cell transplantation. This significant milestone brings hope to individuals facing the challenges of erratic glucose levels associated with brittle Type 1 diabetes.   This designation brings several benefits, including tax advantages, user fee exemptions, and the opportunity for market exclusivity following approval, further supporting the therapy's development.   We at Creative Medical Technology Holdings, Inc. are dedicated to advancing CELZ-101 through regulatory pathways, aiming to transform the therapeutic landscape for patients in need of islet transplantation. This achievement underscores our commitment to leveraging the body's natural regenerative capabilities for lasting health solutions.   https://lnkd.in/d44Gt_Ej #MedicalInnovation #Type1Diabetes #RegenerativeMedicine #FDAApproval #OrphanDrugDesignation #celz #creativemedicaltechnology 

 In recognition of National Glaucoma Awareness Month, we would like to continue to spotlight our portfolio companies working towards better treatments of Glaucoma. At OIS XIII, CEO David Esposito discussed ONL’s lead compound, ONL1204, and its promise across various eye indications. In geographic atrophy (GA), a single injection demonstrated a 42% slowing of lesion growth over six months. In open-angle glaucoma, ONL1204 indicated structural and functional improvement in under 12 months. ONL Therapeutics aims to provide IOP-independent neuroprotection for glaucoma. They plan to report topline results for retinal detachment in April-May, progress to a registrational study for GA in 2024, and explore neuroenhancement in glaucoma with a potential Phase 2 study in 2025. Watch the full video below: #glaucomaawareness #glaucomaawarenessmonth #investintheeye #ophthalmology https://lnkd.in/eHziCgaV

One week until our LIVE webinar on biomarker-driven first-line treatments for metastatic gastric/GEJ adenocarcinoma. Discover recent clinical trial data and personalized care approaches: https://ow.ly/2Pj950TorIa #GastrointestinalOncology #GEJCancer 

Pharma / Biotech news that has caught my eye this week: (Full article links in comments) #1 - Astellas Pharma subsidiary Xyphos Biosciences have partnered with Kelonia Therapeutics in an agreement worth $800m+ with the aim of combining their CAR-T cell therapies for cancer. Kelonia CEO Kevin Friedman and Astellas / Xyphos CSO Adam Pearson described the move as a "revolutionary" bit of collaboration - which should ultimately benefit patients worldwide. Exciting! #2 - UCL & Queen Mary University of London have conducted studies with the aim of earlier Parkinson's diagnosis. The aim of the study is to better understand how the disease progresses, says Katherine Fletcher, leading to faster diagnosis & better treatment for those affected. Love it. and #3 - US-based device manufacturer Reprieve Cardiovascular has secured $42m in funding for its heart failure tech trials. The capital will be directed towards the development of the company’s automated diuretic and fluid management devices, which are designed to remove the fluid in the cardiovascular systems of people suffering from heart failure. A revival, rising from the embers! What's captured your interest? Let me know in the comments! #pharma #biotech #news

𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $13.6 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 Download PDF Brochure @ https://lnkd.in/dY_juu3G The global size of 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $7.5 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2024 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $13.6 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 12.6% from 2024 to 2029 In recent years, there has been a rapid advancement in #medicaltechnology, leading to significant changes in #therapies and #medicine. This progress has contributed to the substantial growth of the companion diagnostics market. Factors such as the increasing importance of companion diagnostics in drug development, the rising prevalence of cancer, and the growing adoption of targeted therapies are driving the growth of the market. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: MESO SCALE DIAGNOSTICS, LLC.      ACROBiosystems    Ventana Medical Systems      RareCyte, Inc.      Toft Group Executive Search, a ZRG Company      Viome Life Sciences      HUB Organoids      Analytical, Life Science & Diagnostics Association (ALDA)      BioChain Institute, Inc.

🚀 Breaking Barriers in Digital Therapeutics 🌐 Join us for a masterclass on the future of early diagnosis in oncology featuring Mike Rosenbluth of Swing Therapeutics, Inc., and Tessy Huss of HLTH Community. The Challenge: Reimbursement Pathways for Digital Therapeutics (DTx) Despite the immense potential of DTx to transform healthcare, a lack of clear reimbursement pathways is hindering their widespread adoption. This impacts not only innovation but also limits patient access to potentially life-saving interventions. The Solution: Exploring Viable Commercialization Strategies Apply To Attend ➡️ https://lnkd.in/eSc3zBCj In the Masterclass, we'll explore: ✅ Overcoming reimbursement challenges in DTx ✅ Innovative business models for accessibility ✅ Future of DTx policies and frameworks Don't miss this opportunity to shape the future of healthcare! 💡 #DigitalTherapeutics #HealthcareInnovation #DTx #FutureOfMedicine Interested in learning more? Comment below! 👇